查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太臨床生物標記市場：分析與預測（2023-2033）
市場調查報告書
商品編碼
1501633

亞太臨床生物標記市場：分析與預測（2023-2033）

Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 53 Pages | 商品交期: 1-5個工作天內

價格

亞太臨床生物標記市場規模預計將從 2023 年的 32.8 億美元增至 2033 年的 79.5 億美元，預測期內複合年成長率為 9.27%。

主要市場統計數據
預測期 2023-2033
2023年評估 32.8億美元
2033年預測 79.5億美元
複合年成長率 9.27%

由於生物技術的進步、醫療保健支出的增加以及對個人化醫療的興趣日益濃厚，亞太地區臨床生物標記市場正在迅速擴大。中國、日本和印度等國家處於領先地位，在研發方面投入大量資金並積極進行臨床試驗活動。癌症和心血管疾病等慢性病盛行率的上升推動了對早期診斷工具和標靶治療的需求。政府的舉措以及學術機構和生物製藥公司之間的合作也支持了市場的成長。此外，次世代定序和生物資訊學等尖端技術的整合正在增強新型生物標記的識別和檢驗，使亞太地區成為臨床生物標記領域的重要中心。

本報告調查了亞太地區臨床生物標記市場，包括市場和技術趨勢、市場影響因素分析、市場規模趨勢和預測、主要國家的詳細分析、競爭格局以及主要企業概況。

目錄

執行摘要

第1章 市場

第2章 市場範圍

第3章調查方法

第4章市場概況

  • 精準醫學中的臨床生物標記方法
  • 臨床生物標記的潛在市場規模
  • COVID-19 對臨床生物標記市場的影響
  • 市場趨勢
    • 將人工智慧融入生物標記發現
    • 生物標記在精準醫學中的使用增加
    • 臨床生物標記測試中使用的技術
    • 臨床生物標記的發現使得疾病的早期診斷成為可能

第5章 區域

  • 概述
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 其他

第6章市場：公司簡介

  • 概述
  • BGI
  • Novogene Co., Ltd.
Product Code: BHP2153SS

Introduction to Asia-Pacific Clinical Biomarkers Market

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$3.28 Billion
2033 Forecast$7.95 Billion
CAGR9.27%

Market Introduction

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

Market Segmentation:

Segmentation 1: by Country

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

  • BGI
  • Novogene Co., Ltd.

Table of Contents

Executive Summary

1 Market

2 Market Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Data Sources
    • 3.1.1 Primary Data Source
    • 3.1.2 Secondary Data Sources
      • 3.1.2.1 Open Sources
  • 3.2 Market Estimation Model
  • 3.3 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Clinical Biomarkers Approaches in Precision Medicine
  • 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
  • 4.4 COVID-19 Impact on Clinical Biomarkers Market
    • 4.4.1 COVID-19 Impact on Market Size
  • 4.5 Market Trends
    • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
    • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
    • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
    • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

  • 5.1 Overview
  • 5.2 Asia-Pacific
    • 5.2.1 China
    • 5.2.2 India
    • 5.2.3 Japan
    • 5.2.4 South Korea
    • 5.2.5 Australia
    • 5.2.6 Rest-of-Asia-Pacific

6 Market - Company Profiles

  • 6.1 Overview
  • 6.2 BGI
    • 6.2.1 Company Overview
    • 6.2.2 Role of BGI in the Clinical Biomarkers Market
    • 6.2.3 Corporate Strategies
      • 6.2.3.1 Product Launch
    • 6.2.4 Analyst's Perspective
  • 6.3 Novogene Co., Ltd.
    • 6.3.1 Company Overview
    • 6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
    • 6.3.3 Analyst's Perspective

List of Figures

  • Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
  • Figure 3: Primary Research Methodology
  • Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 6: Biomarkers Used in Various Clinical Areas
  • Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
  • Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
  • Figure 10: Use of Clinical Biomarkers in Personalized Medicine
  • Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
  • Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
  • Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
  • Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 17: Asia-Pacific: Market Dynamics
  • Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 24: Total Number of Companies Profiled
  • Figure 25: BGI: Service Portfolio
  • Figure 26: Novogene Co., Ltd.: Service Portfolio

List of Tables

  • Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
  • Table 2: List of Product/Service Offered and its Technology